1.25
2.34%
-0.03
Opko Health Inc stock is currently priced at $1.25, with a 24-hour trading volume of 1.80M.
It has seen a -2.34% decreased in the last 24 hours and a -4.21% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.28 pivot point. If it approaches the $1.24 support level, significant changes may occur.
Previous Close:
$1.28
Open:
$1.25
24h Volume:
1.80M
Market Cap:
$871.24M
Revenue:
$863.49M
Net Income/Loss:
$-188.86M
P/E Ratio:
-4.6296
EPS:
-0.27
Net Cash Flow:
$-44.47M
1W Performance:
-3.10%
1M Performance:
-4.21%
6M Performance:
-22.84%
1Y Performance:
-18.30%
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4100
Address
4400 Biscayne Boulevard, Miami, FL
Opko Health Inc Stock (OPK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Dec-15-22 | Initiated | H.C. Wainwright | Buy |
Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
Nov-25-19 | Initiated | Piper Jaffray | Overweight |
Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-21-16 | Reiterated | Standpoint Research | Buy |
Jun-03-16 | Initiated | Standpoint Research | Buy |
Mar-31-16 | Reiterated | Barrington Research | Outperform |
Oct-16-15 | Initiated | JP Morgan | Overweight |
Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
May-12-14 | Reiterated | Oppenheimer | Outperform |
Mar-14-14 | Initiated | Oppenheimer | Outperform |
Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
Oct-22-12 | Initiated | Barrington Research | Outperform |
Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Insider Buying: FROST PHILLIP MD ET AL, Opko Health Inc [OPK] CEO & Chairman invested 100000 shares – Knox ... - Knox Daily
Knox Daily
Med Instruments Stocks' Q1 Earnings: PEN, INGN, OPKO, NVRO - Yahoo Singapore News
Yahoo Singapore News
Opko Health Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
The InvestChronicle
Opko Health Inc (OPK)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News
US Post News
A Trio of FDA Approvals: Almirall, Geron and GSK - BioSpace
BioSpace
There is no doubt that Opko Health Inc (OPK) ticks all the boxes. - SETE News
SETE News
Opko Health Inc Stock (OPK) Financials Data
Opko Health Inc (OPK) Revenue 2024
OPK reported a revenue (TTM) of $863.49 million for the quarter ending December 31, 2023, a -14.01% decline year-over-year.
Opko Health Inc (OPK) Net Income 2024
OPK net income (TTM) was -$188.86 million for the quarter ending December 31, 2023, a +42.49% increase year-over-year.
Opko Health Inc (OPK) Cash Flow 2024
OPK recorded a free cash flow (TTM) of -$44.47 million for the quarter ending December 31, 2023, a +62.87% increase year-over-year.
Opko Health Inc (OPK) Earnings per Share 2024
OPK earnings per share (TTM) was -$0.25 for the quarter ending December 31, 2023, a +43.18% growth year-over-year.
Opko Health Inc Stock (OPK) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
FROST PHILLIP MD ET AL | CEO & Chairman |
May 17 '24 |
Buy |
1.29 |
163,997 |
211,195 |
211,132,222 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 18 '24 |
Buy |
0.87 |
500,000 |
437,100 |
210,968,225 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 14 '24 |
Buy |
0.89 |
500,000 |
444,300 |
210,468,225 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 13 '24 |
Buy |
0.93 |
500,000 |
463,750 |
209,968,225 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 12 '24 |
Buy |
0.93 |
600,000 |
559,380 |
209,468,225 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '24 |
Buy |
0.99 |
500,000 |
496,150 |
208,868,225 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 21 '24 |
Buy |
0.99 |
1,000,000 |
991,700 |
208,368,225 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 07 '24 |
Buy |
0.98 |
1,500,000 |
1,462,800 |
207,368,225 |
KRASNO RICHARD M | Director |
Jan 29 '24 |
Buy |
0.99 |
30,000 |
29,838 |
103,333 |
FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 19 '24 |
Buy |
0.98 |
500,000 |
488,650 |
205,868,225 |
About Opko Health Inc
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Cap:
|
Volume (24h):